International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel

• Status: Unknown status
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Royal Marsden NHS Foundation Trust
• Collaborators: Australasian Gastro-Intestinal Trials Group; Cancer Research UK; ECOG-ACRIN Cancer Research Group; European Organisation for Research and Treatment of Cancer - EORTC; International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel

Criteria

Inclusion Criteria

1. Histologically or cytologically verified, uni-dimensionally measurable, inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus.

2. Age ≥18 years.

3. ECOG Performance status ≤2.

4. Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1.

5. Previous definitive chemoradiotherapy is permitted for early stage squamous cell carcinoma of the anus.

6. HIV+ patients will be considered eligible with a CD4 count of ≥200.

7. Adequate cardiac and respiratory function; absolute neutrophil count (ANC) ≥1.5x10^9/l; white blood cell (WBC) count ≥3x10^9/l; platelets >100x10^9/l; haemoglobin (Hb) ≥9g/dl; creatinine clearance >50ml/minute; serum bilirubin ≤1.5x upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5x ULN; alkaline phosphatase (ALP) ≤3x ULN.

8. Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy.

9. Life expectancy of at least 3 months.

Exclusion Criteria

1. Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded.

2. Previous chemotherapy, radiotherapy or other investigational drug for surgically unresectable locally recurrent or advanced squamous cell carcinoma of the anus

3. Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study.

4. Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.

5. Surgery or palliative radiotherapy within 28 days of randomisation.

6. Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months). Any history of clinically significant cardiac failure.

7. History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.

8. Lack of physical integrity of the gastro-intestinal tract, malabsorption syndrome (naso-gastric or jejunostomy feeding tube is permitted).

9. Acute hepatitis C and/or chronic active hepatitis B infection.

10. Serious active infection requiring i.v. antibiotics at enrolment.

11. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.

12. Other clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this trial.

13. Known hypersensitivity to any of the study drugs or excipients.

14. Known peripheral neuropathy ≥ grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).

15. Pre-existing hearing impairment.

16. Patients planning for a live vaccine.

17. Pregnant or lactating females.